Your browser doesn't support javascript.
loading
I-131-MIBG therapies.
Vöö, Stefan; Bucerius, Jan; Mottaghy, Felix M.
Afiliação
  • Vöö S; Department of Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands. stefan.voo@mumc.nl
Methods ; 55(3): 238-45, 2011 Nov.
Article em En | MEDLINE | ID: mdl-22056346
Metaiodobenzylguanidine (MIBG) is a tracer that selectively targets neuroendocrine cells. On this basis, radiolabeled iodinated-MIBG (I-131-MIBG) has been introduced as a molecular nuclear therapy in the management of neuroendocrine tumors, including neuroblastoma, pheochromocytoma, paraganglioma, neuroendocrine carcinomas, and other rare neuroendocrine tumors. Extensive work has been addressed to develop I-131-MIBG therapy: doses, therapeutic schemes, and efficiency. In this paper, we present an overview on I-131-MIBG therapy, with main focus on different aspects how to perform this treatment.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Neuroendócrino / 3-Iodobenzilguanidina / Radioisótopos do Iodo Tipo de estudo: Diagnostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2011 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Neuroendócrino / 3-Iodobenzilguanidina / Radioisótopos do Iodo Tipo de estudo: Diagnostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2011 Tipo de documento: Article